Novel Therapeutic

all catalysts(0)

nothing on the calendar yet

News(10)

• BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
  BioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.
  fiercebiotech · 23d ago
• Epigenetic editing shows promise against chronic hep B infections
  A new method of CRISPR-based gene editing shows promise in curtailing chronic hepatitis B infections. Its twist is to silence disease-causing genes without altering the underlying DNA. Tune Therape…
  endpoints · 4mo ago
• Dr Garzotto on Aglatimagene Besadenovec Plus Valacyclovir and EBRT in Localized Prostate Cancer
  Mark Garzotto, MD, discusses efficacy data with aglatimagene besadenovec plus valacyclovir and EBRT in localized prostate cancer.
  onclive · 4mo ago
• Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice
  Sanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.
  onclive · 4mo ago
• FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
  The FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.
  onclive · 4mo ago
• FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma
  The FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.
  onclive · 4mo ago
• Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML
  Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.
  onclive · 4mo ago
• Future Directions in Metastatic Castration-Resistant Prostate Cancer
  Dr. Pedro Barata and Dr. Johann De Bono conclude the discussion by reflecting on the evolving future of radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mCRPC) and…
  onclive · 4mo ago
• Personalized Treatment Decision-Making in Metastatic Castration-Resistant Prostate Cancer
  Dr. Johann De Bono and Dr. Pedro Barata discuss the increasing complexity of personalized treatment decision-making in metastatic castration-resistant prostate cancer (mCRPC) as radiopharmaceutical…
  onclive · 4mo ago
• Future Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer
  Dr. Pedro Barata and Dr. Johann De Bono discuss the future direction of radiopharmaceutical therapies and emerging treatment strategies in metastatic castration-resistant prostate cancer (mCRPC).
  onclive · 4mo ago